What does CUSIP 74587V107 represent in this 13F holders report?

CUSIP 74587V107 is the security identifier for PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock used to aggregate holder disclosures.

How many institutions held PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock in Q2 2017?

152 institutional investors reported PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock for Q2 2017. Use the holders table for investor-level position and value details.

PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI)

CUSIP: 74587V107

Q2 2017 13F Holders as of 30 Jun 2017

Type / Class: Equity / Common Stock
Shares outstanding: 49,633,071
Total 13F shares: 35,525,549
Share change: -259,843
Total reported value: $3,104,620,640
Put/Call ratio: 102%
Price per share: $87.40
Number of holders: 152
Value change: +$57,539,772
Number of buys: 92
Number of sells: 73

Quarterly Holders Quick Answers

What is CUSIP 74587V107?
CUSIP 74587V107 identifies PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2017
Previous quarter: Q1 2017

Recent filing periods for CUSIP 74587V107:

Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024

Top shareholders of PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
ADAGE CAPITAL PARTNERS GP, L.L.C.	13F	Company	11%	5,686,668	$211,544,000	—	31 Mar 2017	13F
FMR LLC	13F	Company	7.1%	3,540,729	$131,715,000	—	31 Mar 2017	13F
WELLINGTON MANAGEMENT GROUP LLP	13F	Company	5.1%	2,539,350	$94,464,000	—	31 Mar 2017	13F
VANGUARD GROUP INC	13F	Company	4.9%	2,428,909	$90,355,000	—	31 Mar 2017	13F
ORBIMED ADVISORS LLC	13F	Company	4.5%	2,245,925	$83,548,000	—	31 Mar 2017	13F
JANUS HENDERSON INVESTORS US LLC	13F	Company	4.5%	2,209,599	$82,195,000	—	31 Mar 2017	13F
BlackRock Finance, Inc.	13F	Company	3.5%	1,743,418	$64,856,000	—	31 Mar 2017	13F
Redmile Group, LLC	13F	Company	3.5%	1,725,414	$64,185,000	—	31 Mar 2017	13F
STATE STREET CORP	13F	Company	3%	1,499,747	$55,792,000	—	31 Mar 2017	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	2.3%	1,148,945	$42,741,000	—	31 Mar 2017	13F
PFM Health Sciences, LP	13F	Company	2.1%	1,065,356	$39,631,000	—	31 Mar 2017	13F
SCHRODER INVESTMENT MANAGEMENT GROUP	13F	Company	1.6%	803,926	$30,147,000	—	31 Mar 2017	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	1.6%	805,005	$29,946,000	—	31 Mar 2017	13F
PointState Capital LP	13F	Company	1.6%	771,000	$28,681,000	—	31 Mar 2017	13F
Camber Capital Management LP	13F	Company	1.3%	650,000	$24,180,000	—	31 Mar 2017	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	1.2%	580,500	$21,595,000	—	31 Mar 2017	13F
CITADEL ADVISORS LLC	13F	Company	1.1%	526,659	$19,592,000	—	31 Mar 2017	13F
Tourbillon Capital Partners, L.P.	13F	Company	0.92%	456,097	$16,967,000	—	31 Mar 2017	13F
NORGES BANK	13F	Company	0.79%	392,879	$14,615,000	—	31 Mar 2017	13F
AMERIPRISE FINANCIAL INC	13F	Company	0.77%	384,035	$14,286,000	—	31 Mar 2017	13F
EMERALD ADVISERS, LLC	13F	Company	0.76%	379,289	$14,110,000	—	31 Mar 2017	13F
NORTHERN TRUST CORP	13F	Company	0.67%	334,508	$12,444,000	—	31 Mar 2017	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.64%	316,081	$11,758,000	—	31 Mar 2017	13F
FRED ALGER MANAGEMENT, LLC	13F	Company	0.6%	297,414	$11,064,000	—	31 Mar 2017	13F
EMERALD MUTUAL FUND ADVISERS TRUST	13F	Company	0.53%	260,817	$9,702,000	—	31 Mar 2017	13F
Tekla Capital Management LLC	13F	Company	0.52%	260,200	$9,679,000	—	31 Mar 2017	13F
BB BIOTECH AG	13F	Company	0.49%	245,616	$9,137,000	—	31 Mar 2017	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.47%	232,371	$8,644,000	—	31 Mar 2017	13F
Ghost Tree Capital, LLC	13F	Company	0.45%	225,000	$8,370,000	—	31 Mar 2017	13F
DEUTSCHE BANK AG\	13F	Company	0.42%	207,047	$7,701,000	—	31 Mar 2017	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.42%	206,500	$7,682,000	—	31 Mar 2017	13F
Sio Capital Management, LLC	13F	Company	0.32%	160,064	$5,954,000	—	31 Mar 2017	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.32%	158,170	$5,884,000	—	31 Mar 2017	13F
HBK INVESTMENTS L P	13F	Company	0.32%	156,597	$5,825,000	—	31 Mar 2017	13F
S.c.a. Candriam	13F	Individual	0.31%	154,500	$5,748,000	—	31 Mar 2017	13F
FEDERATED HERMES, INC.	13F	Company	0.31%	152,500	$5,673,000	—	31 Mar 2017	13F
TEACHERS ADVISORS, LLC	13F	Company	0.29%	145,197	$5,401,000	—	31 Mar 2017	13F
Bank of New York Mellon Corp	13F	Company	0.27%	134,224	$4,994,000	—	31 Mar 2017	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.24%	119,312	$4,439,000	—	31 Mar 2017	13F
D. E. Shaw & Co., Inc.	13F	Company	0.21%	106,309	$3,955,000	—	31 Mar 2017	13F
CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM	13F	Company	0.21%	104,900	$3,902,000	—	31 Mar 2017	13F
Boxer Capital, LLC	13F	Company	0.2%	100,000	$3,720,000	—	31 Mar 2017	13F
TIAA CREF INVESTMENT MANAGEMENT LLC	13F	Company	0.19%	95,884	$3,567,000	—	31 Mar 2017	13F
Rock Springs Capital Management LP	13F	Company	0.19%	94,500	$3,515,000	—	31 Mar 2017	13F
Marshall Wace North America L.P.	13F	Company	0.19%	94,090	$3,481,000	—	31 Mar 2017	13F
CAPITAL FUND MANAGEMENT S.A.	13F	Company	0.18%	87,755	$3,264,000	—	31 Mar 2017	13F
Bain Capital Public Equity Management, LLC	13F	Company	0.17%	86,700	$3,225,000	—	31 Mar 2017	13F
JPMORGAN CHASE & CO	13F	Company	0.17%	85,338	$3,174,000	—	31 Mar 2017	13F
CREDIT SUISSE AG/	13F	Company	0.17%	82,644	$3,075,000	—	31 Mar 2017	13F
MORGAN STANLEY	13F	Company	0.15%	76,852	$2,859,000	—	31 Mar 2017	13F

Institutional Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q2 2017

As of 30 Jun 2017, PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) was held by 152 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 35,525,549 shares. The largest 10 holders included PRICE T ROWE ASSOCIATES INC /MD/, ADAGE CAPITAL PARTNERS GP, L.L.C., FMR LLC, VANGUARD GROUP INC, ORBIMED ADVISORS LLC, JANUS HENDERSON GROUP PLC, BlackRock Inc., WELLINGTON MANAGEMENT GROUP LLP, Partner Fund Management, L.P., and MILLENNIUM MANAGEMENT LLC. This page lists 152 institutional shareholders reporting positions in this security for the Q2 2017 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2017 vs Q1 2017 Across Filers

Q1 2017 holders

135

Q2 2017 holders

152

Holder diff

Investor	Q1 2017 Shares	Q2 2017 Shares	Share Diff	Share Chg %	Q1 2017 Value $	Q2 2017 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.